Investigational drug · Phase 2
HLX26
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC Stage IV.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HLX26"
First trial start
2023
Jul 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX26", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC Stage IV
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX26" as an intervention, largest first.
- A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsPivotal-lookingActive, not recruiting
Shanghai Henlius BiotechIndustry
NCT05787613 · 132 participants (planned) · Start Jul 10, 2023 · Primary completion Feb 2026
Drug: HLX26; Serplulimab and 2 more · For: NSCLC Stage IV
Sites: Xuzhou, China; Shanghai, China · 3 sites in all
Shanghai Henlius BiotechIndustry
NCT05078593 · 18 participants · Start Oct 11, 2021 · Primary completion Aug 18, 2023
Drug: HLX26 · For: Solid Tumor, Adult; Lymphoma
Sites: Shanghai, China
Shanghai Henlius BiotechIndustry
NCT05400265 · 9 participants · Start Jul 26, 2022 · Primary completion Aug 31, 2023
Drug: HLX26; HLX10 · For: Adult Solid Tumor
Sites: Xuzhou, China
- Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRCTerminated
Shanghai Henlius BiotechIndustry
NCT05584137 · 2 participants · Start Jun 15, 2023 · Primary completion Dec 31, 2023
Drug: HLX26; HLX10 · For: Colorectal Cancer Metastatic
Sites: Beijing, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.
Liu R, Jing H, Chen Y, et al. · BioDrugs 2026
- Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody.
Du J, Yang Y, Zhu L, et al. · Heliyon 2023
Also in development for NSCLC Stage IV
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.